The novel SSTR2A immunopositivity in our case is of uncertain significance at this point in time as more cases of GLI1-altered mesenchymal tumors will need to be examined for this protein expression to draw conclusions about its potential therapeutic or clinical outcome. Here, GLI1 is linked to mesenchymal cell neoplasm.